A novel splicing mutation in the SLC9A3R1 gene in tumors from ovarian cancer patients

  • Authors:
    • Erica Lorena Kreimann
    • Magdalena Ratajska
    • Alina Kuzniacka
    • Brenda Demacopulo
    • Maciej Stukan
    • Janusz Limon
  • View Affiliations

  • Published online on: October 12, 2015     https://doi.org/10.3892/ol.2015.3796
  • Pages: 3722-3726
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate novel molecular markers that could improve the diagnosis of ovarian cancer patients or be of predictive value. The sequence of the sodium‑hydrogen antiporter 3 regulator 1 (SLC9A3R1) gene that codes for the PDZ2 motif of the Na+/H+ exchanger regulatory factor 1 (NHERF1) protein was analyzed. Changes in migration and cell transformation, and alterations of growth factor signaling pathways have been described in cells lacking endogenous NHERF1 or expressing an isoform lacking the function of the PDZ2 domain. Exons 2 and 3, together with flanking intronic sequences of the SLC9A3R1 gene, were amplified and bi‑directionally sequenced in 31 primary tumor samples from epithelial ovarian cancer patients. In total, 3 different previously undescribed mutations were detected in 8 out of 31 serous adenocarcinoma tumor samples (25.8%). Bioinformatics analysis predicted a significant effect in the splicing process as a result of the mutations that could disrupt the NHERF1 PDZ2 domain. Point mutations in consensus splicing recognition are a major cause of the splicing defects that are found in several diseases, including cancer. It has previously been shown that a lack of exon 2 and disruption of the PDZ2 domain contribute to cell transformation and leads to modifications in the physiological regulation of the conformational state of NHERF1. Further studies in bigger groups of ovarian cancer patients will determine the importance of this mutation in disease progression and patient survival.
View Figures
View References

Related Articles

Journal Cover

December-2015
Volume 10 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kreimann EL, Ratajska M, Kuzniacka A, Demacopulo B, Stukan M and Limon J: A novel splicing mutation in the SLC9A3R1 gene in tumors from ovarian cancer patients. Oncol Lett 10: 3722-3726, 2015.
APA
Kreimann, E.L., Ratajska, M., Kuzniacka, A., Demacopulo, B., Stukan, M., & Limon, J. (2015). A novel splicing mutation in the SLC9A3R1 gene in tumors from ovarian cancer patients. Oncology Letters, 10, 3722-3726. https://doi.org/10.3892/ol.2015.3796
MLA
Kreimann, E. L., Ratajska, M., Kuzniacka, A., Demacopulo, B., Stukan, M., Limon, J."A novel splicing mutation in the SLC9A3R1 gene in tumors from ovarian cancer patients". Oncology Letters 10.6 (2015): 3722-3726.
Chicago
Kreimann, E. L., Ratajska, M., Kuzniacka, A., Demacopulo, B., Stukan, M., Limon, J."A novel splicing mutation in the SLC9A3R1 gene in tumors from ovarian cancer patients". Oncology Letters 10, no. 6 (2015): 3722-3726. https://doi.org/10.3892/ol.2015.3796